huberman lab bpc 157 andrew Peptide Therapy Explained with Dr. Andrew Huberman FDA panel votes to ease

FAQs: Peptide Therapy vs

Unlike pharmacological interventions that target single receptors or pathways, GHK-Cus multi-gene modulation touches many of the hallmarks of aging simultaneously: Genomic instability (DNA repair gene upregulation) Epigenetic alterations (chromatin remodeling via altered transcription factor activity) Loss of proteostasis (chaperone and proteasome pathway modulation) Cellular senescence (anti-apoptotic and anti-senescence gene networks) Altered intercellular communication (anti-inflammatory cytokine modulation) This positions GHK-Cu within what researchers increasingly call multi-hallmark peptide therapy a conceptual framework that prioritizes compounds acting across multiple aging mechanisms simultaneously

PMID 17258528

Funding Open access funding provided by the Scientific and Technological Research Council of Trkiye (TBTAK)